| 日付 | 保有者名 | 取引株数 | 金額レンジ ($) | 取引種別 | 価格レンジ ($) | 届出終了時の株数 | % 変化 |
|---|---|---|---|---|---|---|---|
| 2026-05-04 | Dr. Marcella Kuhlman RuddyChief Medical Officer | -1.07k | 31.95k | Automatic Disposition | 30.00 | 23.90k | -4.27% |
| 2026-04-01 | Dr. Marcella Kuhlman RuddyChief Medical Officer | -1,000.00 | 31.05k | Automatic Disposition | 31.05 | 24.96k | -3.85% |
| 2026-03-06 | Dr. Marcella Kuhlman RuddyChief Medical Officer | -10.00k | 300.00k | Automatic Disposition | 30.00 | 25.96k | -27.81% |
| 2026-03-06 | Dr. Peter McNamaraChief Scientific Officer | -2.72k | 72.34k | Derivative Exercise and Sale | 2.38 - 30.00 | 17.64k | - |
| 2026-03-06 | Dr. Peter McNamaraChief Scientific Officer | -3.55k | 107.49k | Automatic Disposition | 30.00 - 35.00 | 17.64k | -16.74% |
| 2026-03-03 | Dr. Peter McNamaraChief Scientific Officer | -3.30k | 77.63k | Automatic Disposition | 22.06 - 25.00 | 21.19k | -13.47% |
| 2026-02-11 | Dr. Alise S. ReicinPresident, CEO, Secretary & Director | 2.50k | 52.75k | 買い | 21.10 | 314.56k | 0.80% |
| 2026-02-10 | Dr. Marc SchwabishChief Business Officer | 4.50k | 10.71k | Derivative Exercise and Retained Stock | 2.38 | 12.26k | 58.03% |
| 2026-02-10 | Mr. Daniel LochnerCFO | 6.00k | 129.66k | 買い | 21.61 | 14.57k | 70.05% |
| 2026-02-04 | Dr. Marc SchwabishChief Business Officer | -1.62k | 37.59k | Sale to Issuer | 23.22 | 7.76k | -17.27% |
| 2026-02-04 | Dr. Marcella Kuhlman RuddyChief Medical Officer | -2.06k | 47.93k | Sale to Issuer | 23.22 | 35.96k | -5.43% |
| 2026-02-04 | Dr. Alise S. ReicinPresident, CEO, Secretary & Director | -4.10k | 95.29k | Sale to Issuer | 23.22 | 312.06k | -1.30% |
| 2026-02-04 | Dr. Peter McNamaraChief Scientific Officer | -1.75k | 40.59k | Sale to Issuer | 23.22 | 24.49k | -6.66% |
| 2026-02-04 | Mr. Daniel LochnerCFO | -2.08k | 48.23k | Sale to Issuer | 23.22 | 8.57k | -19.52% |
| 2025-12-31 | Dr. Alise S. ReicinPresident, CEO, Secretary & Director | 10.97k | 26.10k | Derivative Exercise and Retained Stock | 2.38 | 304.15k | 3.74% |
| 2025-12-22 | Dr. Peter McNamaraChief Scientific Officer | 7.00k | 20.86k | Derivative Exercise and Retained Stock | 2.98 | 21.19k | 49.34% |
| 2025-06-20 | Dr. Alise S. ReicinPresident, CEO, Secretary & Director | -859.00 | 17.02k | Sale to Issuer | 19.81 | 293.18k | -0.29% |
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約
すでにアカウントをお持ちですか? サインイン
アカウントをお持ちでないですか? 登録
登録することで、ADVFN の 利用規約 を読み、理解し、同意したこと、および私が個人投資家であることを確認します。